Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.

Most patients with pancreatic ductal adenocarcinoma (PDAC) have unresectable cancers with a dismal prognosis, in which cohort chemotherapy is the primary treatment. T cell immune adaption is critical for tumor immune escape and prognosis of this disease. The present study aimed to determine the correlation between peripheral T cell subset distribution in patients with unresectable PDAC and their response to chemotherapy. Two hundred and twelve patients with unresectable PDAC were included whose blood samples were collected for analysis of T cell subsets, including CD3+, CD4+, CD8+, CD8+CD28+ and CD4+CD25+CD127 T cells by flow cytometry before and after gemcitabine-based chemotherapy. Enzyme-linked immunosorbent assay was used to detect the expression levels of tumor growth factor (TGF)-β1, interleukin (IL)-6 and IL-17A in the patients before and after chemotherapy. Univariate and multivariate analyses found that an initial CD4/CD8 ratio or T regulatory (Treg) cell level before any treatment was associated with the prognosis of unresectable PDAC. After two cycles of chemotherapy, there was no significant change in percentages of T cell subsets, except elevation to a higher level of CD3+ T cells. Decreased Tregs or CD4/CD8 ratio after two cycles of chemotherapy predicts a longer overall survival (OS). Levels of Tregs in stable disease (SD) and partial remission (PR) cases significantly decreased after chemotherapy, but increased in progressive disease (PD) patients. There was no correlation between Tregs and the expression level of either TGF-β1 or IL-6. IL-17A expression was elevated in Treg-decreased patients, whereas IL-17A was reduced in Treg-increased patients after chemotherapy. The circulating signature of T cell subsets can predict OS and chemotherapeutic response in patients with unresectable PDAC, and may be attributable to the plasticity of T cell subsets.

[1]  P. Neven,et al.  Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty , 2017, Breast Cancer Research.

[2]  S. H. van der Burg,et al.  Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients , 2016, Oncoimmunology.

[3]  T. Shichinohe,et al.  Clinical impact of chemotherapy to improve tumor microenvironment of pancreatic cancer , 2016, World journal of gastrointestinal oncology.

[4]  D. Speiser,et al.  Regulatory circuits of T cell function in cancer , 2016, Nature Reviews Immunology.

[5]  V. Boussiotis,et al.  Clinical significance of T cell metabolic reprogramming in cancer , 2016, Clinical and Translational Medicine.

[6]  E. Elkord,et al.  Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting , 2016, Vaccines.

[7]  R. Qin,et al.  Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells , 2016, Autophagy.

[8]  Chun-tao Wu,et al.  Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma , 2016, The British journal of surgery.

[9]  Zuqiang Liu,et al.  Which patients with para-aortic lymph node (LN16) metastasis will truly benefit from curative pancreaticoduodenectomy for pancreatic head cancer? , 2016, Oncotarget.

[10]  E. Aandahl,et al.  Regulatory T cells that co-express RORγt and FOXP3 are pro-inflammatory and immunosuppressive and expand in human pancreatic cancer , 2016, Oncoimmunology.

[11]  K. Ohshima,et al.  A High RORγT/CD3 Ratio is a Strong Prognostic Factor for Postoperative Survival in Advanced Colorectal Cancer: Analysis of Helper T Cell Lymphocytes (Th1, Th2, Th17 and Regulatory T Cells) , 2016, Annals of Surgical Oncology.

[12]  A. Viola,et al.  T Cells and Cancer: How Metabolism Shapes Immunity , 2016, Front. Immunol..

[13]  N. Pavlova,et al.  The Emerging Hallmarks of Cancer Metabolism. , 2016, Cell metabolism.

[14]  Mason R. Mackey,et al.  Basal autophagy maintains pancreatic acinar cell homeostasis and protein synthesis and prevents ER stress , 2015, Proceedings of the National Academy of Sciences.

[15]  S. Hugues,et al.  Th17 Cell Plasticity and Functions in Cancer Immunity , 2015, BioMed research international.

[16]  A. Orekhov,et al.  T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview , 2015, BioMed research international.

[17]  F. Ghiringhelli,et al.  Cytotoxic effects of chemotherapy on cancer and immune cells: how can it be modulated to generate novel therapeutic strategies? , 2015, Future oncology.

[18]  S. Biswas.  Metabolic Reprogramming of Immune Cells in Cancer Progression. , 2015, Immunity.

[19]  J. Locasale,et al.  Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses , 2015, Cell.

[20]  G. Nuovo,et al.  The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer , 2015, BMC Cancer.

[21]  Xiaofang Wang,et al.  Changes of Th17/Treg cell and related cytokines in pancreatic cancer patients. , 2015, International journal of clinical and experimental pathology.

[22]  B. Bernstein,et al.  Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation , 2015, Nature.

[23]  Qunyuan Zhang,et al.  CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome , 2015, Oncotarget.

[24]  J. McClintick,et al.  Pachymic Acid Inhibits Growth and Induces Apoptosis of Pancreatic Cancer In Vitro and In Vivo by Targeting ER Stress , 2015, PloS one.

[25]  Bo Kong,et al.  A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels , 2015, Scientific Reports.

[26]  J. Long,et al.  Abnormal distribution of peripheral lymphocyte subsets induced by PDAC modulates overall survival. , 2014, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[27]  M. Lesina,et al.  The immune network in pancreatic cancer development and progression , 2014, Oncogene.

[28]  Chunxiao Wu,et al.  Cancer statistics: current diagnosis and treatment of pancreatic cancer in Shanghai, China. , 2014, Cancer letters.

[29]  I. Endo,et al.  Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal Adenocarcinoma , 2014, Annals of Surgical Oncology.

[30]  D. Alizadeh,et al.  The Multifaceted Role of Th17 Lymphocytes and Their Associated Cytokines in Cancer , 2013, Clinical & developmental immunology.

[31]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[32]  Jiyuan Zhang,et al.  Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma , 2013, Hepatology.

[33]  J. Matsumoto,et al.  Novel aspects of preoperative chemoradiation therapy improving anti‐tumor immunity in pancreatic cancer , 2013, Cancer science.

[34]  Linda V. Sinclair,et al.  Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation , 2013, Nature Immunology.

[35]  J. Long,et al.  Stroma and pancreatic ductal adenocarcinoma: an interaction loop. , 2012, Biochimica et biophysica acta.

[36]  Bond-Smith Giles,et al.  Only women with symptoms need to have their breast implants removed, says government , 2012 .

[37]  H. Toyokawa,et al.  Circulating CD4+CD25+ Regulatory T Cells in Patients With Pancreatic Cancer , 2012, Pancreas.

[38]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[39]  G. Semenza,et al.  Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1 , 2011, Cell.

[40]  T. Mak,et al.  Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.

[41]  W. Zou,et al.  TH17 cells in tumour immunity and immunotherapy , 2010, Nature Reviews Immunology.

[42]  A. Rudensky,et al.  CD4+ Regulatory T Cells Control TH17 Responses in a Stat3-Dependent Manner , 2009, Science.

[43]  R. Vonderheide,et al.  Immunosurveillance of pancreatic adenocarcinoma: insights from genetically engineered mouse models of cancer. , 2009, Cancer letters.

[44]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[45]  Helen Hickey,et al.  A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. , 2004, The New England journal of medicine.

[46]  R. DePinho,et al.  Pancreatic cancer biology and genetics , 2002, Nature Reviews Cancer.

[47]  T. Whiteside,et al.  Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  Jianying Zhou,et al.  Treg/Th17 imbalance in malignant pleural effusion partially predicts poor prognosis. , 2015, Oncology reports.

[49]  Zuqiang Liu,et al.  Blood Neutrophil–Lymphocyte Ratio Predicts Survival in Patients with Advanced Pancreatic Cancer Treated with Chemotherapy , 2014, Annals of Surgical Oncology.

[50]  R. Deberardinis,et al.  The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. , 2008, Cell metabolism.